Top Analyst Upgrades and Downgrades: Bats, Eli Lilly, Gap, Hasbro, JD.com, Nike, Pfizer, SolarCity and More

Investing

Published: May 10, 2016 8:55 am

Last Updated: January 13, 2020 9:38 am

Stocks were indicated to open higher on Tuesday in what looks like a broad rally. With the Dow still down about 500 points from the April highs, investors still seem to be looking for opportunities ahead. Buying the dips has not died.

24/7 Wall St. reviews dozens of analyst research reports each morning of the week to find new investing and trading ideas. Some of these analyst reports cover stocks to buy, while other reports cover stocks to sell or avoid.

These are the top analyst upgrades, downgrades and initiations seen on Tuesday morning:

Bats Global Markets Inc. (BATS) saw its post-IPO quiet period come to an end. The stock was started as Neutral with a $28 price objective at Merrill Lynch. Jefferies started it as Hold with a $28 price target. Morgan Stanley started it as Equal Weight.

Eli Lilly & Co. (NYSE: LLY) was added to the prized US 1 list (focus list) at Merrill Lynch. The firm called it a compelling entry point and event path into year-end with solid risk/reward into its breast cancer (abema breast cancer data at ASCO) and Alzheimer’s updates. It has a consensus analyst price target of $95.95 and a 52-week trading range of $67.88 to $92.85.